Last reviewed · How we verify

NCT05164367

Pharmacokinetics of Atropine Oral Gel

Completed EARLY_PHASE1 Last updated 18 December 2024
What this trial tests

EARLY_PHASE1 trial testing Atropine sulfate gel (0.01%) in Cerebral Palsy in 10 participants. Completed in 10 December 2024.

Timeline
1 October 2022
Primary endpoint
30 June 2023
10 December 2024

Quick facts

Lead sponsorUniversity of Utah
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 October 2022
Primary completion30 June 2023
Estimated completion10 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Utah

Who can join

Adults 18 to 50, any sex, with Cerebral Palsy or Sialorrhea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the single-dose pharmacokinetics of atropine gel formulation after topical administration in the oral cavity of healthy adults.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers.
    Parrot M, Yathavan B, Averin O, Hoggard L, et al · · 2024 · cited 3× · PMID 38465519 · DOI 10.1111/cts.13753

Verify or expand the search:

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other University of Utah trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05164367.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing